Genmab gains on promising early success for daratumumab PhIII in multiple myeloma, but questions linger
Shares of Copenhagen-based Genmab surged Thursday morning as investigators declared that its late-stage combo drug using daratumumab (Darzalex) hit the primary endpoint for treating multiple myeloma as a frontline therapy at the interim readout stage. Researchers now plan to unblind the data as Genmab {CPH: $GEN} and J&J $JNJ hustle along with a new marketing application.
Genmab shares $GEN shot up 8% on the news.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.